Semenza GL (2008) A new weapon for attacking tumor blood vessels. N Engl J Med 358(19):2066–2067

Article  CAS  PubMed  Google Scholar 

Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL et al (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 26(21):3523–3529

Article  CAS  PubMed  Google Scholar 

Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R et al (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017

Article  CAS  PubMed  Google Scholar 

Wu S, Kim C, Baer L, Zhu X (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21(8):1381–1389

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49(2):186–193

Article  CAS  PubMed  Google Scholar 

Ando Y, Kawaoka T, Kosaka M, Shirane Y, Johira Y, Miura R et al (2023) Risk factors for early onset of Proteinuria in patients receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Liver Cancer 12(3):251–261

Article  CAS  PubMed  Google Scholar 

Kanbayashi Y, Ishikawa T, Tabuchi Y, Sakaguchi K, Ouchi Y, Otsuji E et al (2020) Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: a single-institution retrospective analysis. Sci Rep 10(1):2011

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ikesue H, Yamamoto H, Hirabatake M, Hashida T, Chung H, Inokuma T et al (2022) Risk factors of Proteinuria in patients with Hepatocellular Carcinoma receiving Lenvatinib. Biol Pharm Bull 45(3):333–338

Article  CAS  PubMed  Google Scholar 

Ikesue H, Yamaoka K, Matsumoto A, Hirabatake M, Muroi N, Yamasaki T et al (2022) Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. Cancer Chemother Pharmacol 89(6):833–838

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomita Y, Uemura H, Fujimoto H, Kanayama H-o, Shinohara N, Nakazawa H et al (2011) Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma. Eur J Cancer 47(17):2592–2602

Article  CAS  PubMed  Google Scholar 

Bollée G, Patey N, Cazajous G, Robert C, Goujon J-M, Fakhouri F et al (2009) Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transpl 24(2):682–685

Article  Google Scholar 

Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC (2010) VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 46(2):439–448

Article  CAS  PubMed  Google Scholar 

Fu Y, Saxu R, Ridwan KA, Yao J, Chen X, Xu X et al (2022) Losartan alleviates the side effects and maintains the Anticancer activity of Axitinib. Molecules. ;27(9)

Lankhorst S, Kappers MHW, van Esch JHM, Smedts FMM, Sleijfer S, Mathijssen RHJ et al (2014) Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension 64(6):1282–1289

Article  CAS  PubMed  Google Scholar 

Tinning AR, Bengtsen C, Jensen NV, Bastholt L, Jensen BL, Madsen K (2018) Pazopanib-Induced hypertension in patients with renal cell carcinoma is Associated with low urine excretion of NO metabolites. Hypertension 71(3):473–480

Article  CAS  PubMed  Google Scholar 

Nihei S, Ikeda T, Aoki T, Murasato F, Yaegashi M, Asahi K et al (2023) Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer. Cancer Chemother Pharmacol 91(5):427–434

Article  CAS  PubMed  Google Scholar 

Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P et al (2012) The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55(17):7849–7861

Article  CAS  PubMed  Google Scholar 

Bedan M, Grimm D, Wehland M, Simonsen U, Infanger M, Krüger M (2018) A focus on Macitentan in the treatment of pulmonary arterial hypertension. Basic Clin Pharmacol Toxicol 123(2):103–113

Article  CAS  PubMed  Google Scholar 

Thenappan T, Ormiston ML, Ryan JJ, Archer SL (2018) Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 360:j5492

Article  PubMed  PubMed Central  Google Scholar 

Carson CC (2003) Long-term use of sildenafil. Expert Opin Pharmacother 4(3):397–405

Article  CAS  PubMed  Google Scholar 

Chen X, Ji ZL, Chen YZ (2002) TTD: therapeutic target database. Nucleic Acids Res 30(1):412–415

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corbin JD, Francis SH, Webb DJ (2002) Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology. ;60(2 Suppl 2).

Voigt J-P, Bramlage P, Fink H (2007) Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats. Eur J Pharmacol 564(1–3):131–137

Article  CAS  PubMed  Google Scholar 

Waeber B, Burnier M (2003) AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Expert Rev Cardiovasc Ther 1(1):23–33

Article  CAS  PubMed  Google Scholar 

Dol F, Martin G, Staels B, Mares AM, Cazaubon C, Nisato D et al (2001) Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 38(3):395–405

Article  CAS  PubMed  Google Scholar 

Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S et al (2004) Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology 55(2):195–203

Article  PubMed  Google Scholar 

Andújar-Sánchez M, Jara-Pérez V, Cámara-Artigas A (2007) Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett 581(18):3449–3454

Article  PubMed  Google Scholar 

Dalkas GA, Marchand D, Galleyrand J-C, Martinez J, Spyroulias GA, Cordopatis P et al (2010) Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme. J Pept Sci 16(2):91–97

Article  CAS  PubMed  Google Scholar 

Natesh R, Schwager SLU, Evans HR, Sturrock ED, Acharya KR (2004) Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 43(27):8718–8724

Article  CAS  PubMed  Google Scholar 

Brower GL, Levick SP, Janicki JS (2007) Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol 292(6):H3057–H64

Article  CAS  PubMed  Google Scholar 

Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y (2008) Captopril attenuates matrix metalloproteinase-2 and – 9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci 108(4):487–494

Article  CAS  PubMed  Google Scholar